Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
09/2003
09/04/2003CA2476846A1 Method for detection of leptin receptor ligands
09/04/2003CA2476782A1 Carboxyfullerenes and methods of use thereof
09/04/2003CA2476316A1 Beta3-adrenergic receptor agonists
09/04/2003CA2475655A1 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
09/04/2003CA2475433A1 Trpm-2 antisense therapy using an oligonucleotide having 2'-o-(2-methoxyl)ethyl modifications
09/04/2003CA2475299A1 Thiazole derivatives as npy receptor antagonists
09/04/2003CA2474805A1 Combinations of (a) an atp-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents
09/04/2003CA2459155A1 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
09/03/2003EP1340979A2 Neuropeptide receptor and uses thereof
09/03/2003EP1340510A1 Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
09/03/2003EP1340509A1 Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
09/03/2003EP1340508A1 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
09/03/2003EP1340492A1 Aerosol formulations for pulmonary administration of medicaments having systemic effects
09/03/2003EP1340079A2 S. aureus protein staau-r2, gene encoding it and uses thereof
09/03/2003EP1339879A2 Method of identifying a polymorphism in cyp2d6
09/03/2003EP1339878A2 Method for identifying modulators of transcription
09/03/2003EP1339866A2 Human testis specific serine/threonine kinase
09/03/2003EP1339854A2 Lipid metabolism enzymes
09/03/2003EP1339846A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
09/03/2003EP1339844A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
09/03/2003EP1339843A2 Human transporter proteins nucleic acid molecules encoding them and uses thereof
09/03/2003EP1339842A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
09/03/2003EP1339840A2 Schizophrenia-related voltage-gated ion channel gene and protein
09/03/2003EP1339836A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
09/03/2003EP1339834A2 Enzymes
09/03/2003EP1339754A1 Multicomponent compositions containing chitosan and methods of preparing same
09/03/2003EP1339753A2 Percarboxylated polysaccharides, and a process for their preparation
09/03/2003EP1339748A2 G-protein coupled receptors
09/03/2003EP1339717A1 Novel carbamate-substituted pyrazolopyridine derivatives
09/03/2003EP1339716A1 Novel lactame-substituted pyrazolopyridine derivatives
09/03/2003EP1339714A1 Novel sulfonamide-substituted pyrazolopyridine derivatives
09/03/2003EP1339711A1 Aminothiazoles and their use as adenosine receptor antagonists
09/03/2003EP1339708A2 Indole-type inhibitors of p38 kinase
09/03/2003EP1339686A2 Cyanoguanidine prodrugs
09/03/2003EP1339684A1 Mch antagonists and their use in the treatment of obesity
09/03/2003EP1339663A2 Naphthalene derivatives
09/03/2003EP1339502A1 Method for producing a partial or complete active ingredient coating on and in implants and onplants
09/03/2003EP1339458A2 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
09/03/2003EP1339438A2 Methods for preventing transplant rejection in the eye
09/03/2003EP1339429A2 Composition containing statins and calcium for improved cardiovascular health
09/03/2003EP1339428A1 Inhalation of nitric oxide
09/03/2003EP1339416A1 Trace elements
09/03/2003EP1339413A1 Complexes of phosphate derivatives
09/03/2003EP1339405A1 Use of anti-muscarinic agents and calcium channel blockers in combination
09/03/2003EP1339404A2 Composition and method
09/03/2003EP1339399A2 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
09/03/2003EP1339398A2 Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing compounds
09/03/2003EP1339394A1 Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
09/03/2003EP1339388A1 Particulate inhalation carrier
09/03/2003EP1339373A1 Use of moulding compounds for producing treatment devices
09/03/2003EP1339349A2 Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants
09/03/2003EP1196414B1 Prodrugs of carbamate inhibitors of impdh
09/03/2003EP1183046B1 Aminotetralin derivative for the therapy of cardiovascular diseases
09/03/2003EP1140187B1 Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications
09/03/2003EP1140048B1 Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases
09/03/2003EP1019021B1 Stabilized preparations for use in metered dose inhalers
09/03/2003EP0977733B1 Arylsulfonylamino hydroxamic acid derivatives
09/03/2003EP0925070B1 Antifungal combination therapy
09/03/2003EP0920301B1 Therapeutic or hygienic compositions with controlled and prolonged release of the active principle(s), in particular for ophthalmic use
09/03/2003EP0914614B1 CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrPsc
09/03/2003EP0833670B1 Vaccine against rotavirus infection comprising peptides of viral enterotoxin nsp4
09/03/2003EP0833612B1 New pharmaceutical composition with anaesthetic effect
09/03/2003CN1440424A Antibody selective for tumor necrosis factor-related apoptosis-inducing ligand receptor and use thereof
09/03/2003CN1440420A Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
09/03/2003CN1440396A Colchinol derivatives as angiogenesis inhibitors
09/03/2003CN1440390A Substituted diamide derivatives useful as motilin antagonists
09/03/2003CN1440388A Beta crystalline form of perindopril tert-butylamine salt, preparation method and pharmaceutical compositions containing same
09/03/2003CN1440387A Alpha crystalline form of perindopril tert-butyllamine salt
09/03/2003CN1440386A Gamma crystalline form of perindopril tert-butylamine salt, preparation method and pharmaceutical compositions containing same
09/03/2003CN1440291A Pharmaceutical composition based on non-steroid anti-inflammatory agent
09/03/2003CN1440287A Method of treating peripheral vascular diseases, peripheral neuropathies, and automatic neuropathies
09/03/2003CN1440283A Combination of organic compounds
09/03/2003CN1440276A Use of oligosaccharides to stimulate beta-endorphin production
09/03/2003CN1440240A Preparation for prevention and/or treatment of vascular disorders
09/03/2003CN1439313A Joint healthy beverage or food and preparation thereof
09/03/2003CN1119994C Oral preparation for prophylactic and therapeutic treatment of helicobacter sp. infection
09/02/2003US6614831 Mounting arrangement for auxiliary burner or lance
09/02/2003US6613879 FAP-activated anti-tumour compounds
09/02/2003US6613802 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
09/02/2003US6613790 Prodrugs of COX-2 inhibitors
09/02/2003US6613788 Transdermal patch to systemically deliver effective dose of histamine comprising histamine and controlled release preparation which releases drug over period of time sufficient to obtain stable elevated levels in circulating blood
09/02/2003US6613783 Non-systemic control of parasites
09/02/2003US6613775 Imidazo[1,2-a]pyridine compounds
09/02/2003US6613753 Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
09/02/2003US6613572 Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
09/02/2003US6613354 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
09/02/2003US6613322 Administering enzyme inhibitors
08/2003
08/28/2003WO2003071281A2 Estrogen receptor interaction with a transcription factor
08/28/2003WO2003071273A1 Method of detecting bond between vitamin d3 derivative and vitamin d3 receptor
08/28/2003WO2003071268A2 Method for discovering pharmacologically active substances
08/28/2003WO2003070976A2 Methods for determining the influence of protein binding on antiretroviral activity
08/28/2003WO2003070971A2 Modulators of paraptosis and related methods
08/28/2003WO2003070965A2 The eaat2 promoter and uses thereof
08/28/2003WO2003070883A2 Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
08/28/2003WO2003070772A1 Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments
08/28/2003WO2003070771A1 Rrp sequences and knockout mice and uses thereof
08/28/2003WO2003070281A1 Prostaglandin composition for the treatment of erectile dysfunction
08/28/2003WO2003070279A1 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
08/28/2003WO2003070278A1 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
08/28/2003WO2003070276A1 A preparation and method for weight reduction
1 ... 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 ... 1151